Artwork

Content provided by podcast@nature.com and Springer Nature Limited. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by podcast@nature.com and Springer Nature Limited or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

CureVac disappoints in COVID vaccine trial

13:29
 
Share
 

Manage episode 295320190 series 3137
Content provided by podcast@nature.com and Springer Nature Limited. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by podcast@nature.com and Springer Nature Limited or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

After a slew of wildly successful vaccine trials, this week marked a more underwhelming result. The third mRNA vaccine to complete phase three trials, developed by CureVac, is just 47% effective at staving off disease according to preliminary data. This is a stark contrast with previous mRNA vaccines from Moderna and Pfizer BioNtec which returned around twice that efficacy in their trials. In this episode of Coronapod, we ask why the CureVac vaccine has faltered, and what this might mean for the future of the pandemic and mRNA vaccine development.


News: CureVac COVID vaccine let-down spotlights mRNA design challenges

News Feature: How COVID unlocked the power of RNA vaccines


Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.



Hosted on Acast. See acast.com/privacy for more information.

  continue reading

823 episodes

Artwork

CureVac disappoints in COVID vaccine trial

Nature Podcast

151,015 subscribers

published

iconShare
 
Manage episode 295320190 series 3137
Content provided by podcast@nature.com and Springer Nature Limited. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by podcast@nature.com and Springer Nature Limited or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

After a slew of wildly successful vaccine trials, this week marked a more underwhelming result. The third mRNA vaccine to complete phase three trials, developed by CureVac, is just 47% effective at staving off disease according to preliminary data. This is a stark contrast with previous mRNA vaccines from Moderna and Pfizer BioNtec which returned around twice that efficacy in their trials. In this episode of Coronapod, we ask why the CureVac vaccine has faltered, and what this might mean for the future of the pandemic and mRNA vaccine development.


News: CureVac COVID vaccine let-down spotlights mRNA design challenges

News Feature: How COVID unlocked the power of RNA vaccines


Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.



Hosted on Acast. See acast.com/privacy for more information.

  continue reading

823 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide